New Delhi: The NIPER Boehringer MoU strengthened pharmaceutical education and research, while authorities launched AMRITVA Cohort 2 with grants for five innovators.
Officials signed the agreement between the National Institute of Pharmaceutical Education and Research, Raebareli, and Boehringer Ingelheim India Pvt. Ltd. Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, attended the event in New Delhi.
The NIPER Boehringer MoU created a structured framework for academic and research collaboration. It covered pharmaceutical technologies, novel drug delivery systems, academic exchange and capability-building programmes. In addition, the partnership included NIPER’s Centre of Excellence for Novel Drug Delivery Systems.
At the same event, officials launched Cohort 2 of AMRITVA, or Alliance for Medicinal Research, Innovation, Translation and Value Acceleration. The programme aims to convert research outcomes into viable pharmaceutical products and new ventures.
NIPER Boehringer MoU drives AMRITVA industry-academia push
The Startup Incubation and Innovation Centre at IIT Kanpur runs AMRITVA in partnership with NIPER Raebareli. Moreover, Boehringer Ingelheim India supports the initiative under its Corporate Social Responsibility programme.
Under Cohort 2, authorities selected five innovators for financial assistance. They granted support to three faculty-led projects and two research scholar-led projects to speed up commercialisation.
During his address, Manoj Joshi stressed the need for strong industry-academia collaboration. He said such partnerships can strengthen the research-to-market pipeline. He added that they can boost domestic innovation, promote entrepreneurship and expand access to affordable healthcare.
As part of the collaboration, Boehringer Ingelheim will give researchers access to its opnMe open science platform. This move will enable scientific exchange and accelerate healthcare innovation.
Meanwhile, the Department of Pharmaceuticals continues to push the sector towards a value-driven model. It is backing policy reforms, infrastructure growth and incubation-led commercialisation in line with Viksit Bharat 2047.
